Exhibit 10.8I
GlaxoSmithKline One Franklin Plaza P.O. Box 7929 Philadelphia, PA 19101-7929 Tel. 215 751 4000 Fax. 215 751 3400 www.gsk.com |
August 1, 2001 |
NPS Pharmaceuticals, Inc.
420 Chipeta Way
Salt Lake City, Utah 84108
RE: Amendment Agreement to Amend the January 24, 2000 Amendment Agreement
Dear Sirs:
• In the second bullet, delete the “fifth, sixth, and seventh RESEARCH years” and insert therefor the words “fifth and sixth RESEARCH years, and at a level of one hundred seventy five thousand U.S. dollars (U.S. $175,000) per NPS FTE who is a lab personnel and at a level of one hundred fifty thousand U.S. dollars (U.S. $150,000) per NPS FTE who is a non-lab based consultant for the seventh RESEARCH year and at a level of two hundred twenty five thousand U.S. dollars (U.S. $225,000) per NPS FTE who is a non-lab based consultant for the eighth RESEARCH year, provided that it is understood that there will only be a total of two (2) NPS FTE’s during the seventh RESEARCH year and only a total of four (4) NPS FTE’s during the eighth RESEARCH year, and the levels outlined above will be applied on a pro-rata basis depending on the type of NPS FTE utilized.
• This Amendment Agreement shall be retroactively effective as of November 1, 2000.
Please indicate your acceptance of this January 24, 2000 Amendment Agreement by signing and dating the duplicate copies of this letter below and returning one such fully executed copy to GSK.
Very truly yours, | ||
SMITHKLINE BEECHAM CORPORATION (a GlaxoSmithKline Company) | ||
By: | /s/ Donald F. Parman | |
Donald F. Parman | ||
Title: | Secretary | |
Date: | August 1, 2001 |
AGREED TO AND ACCEPTED: NPS PHARMACEUTICALS, INC. | ||
By: | /s/ E. F. Nemith | |
E. F. Nemith | ||
Title: | CSO | |
Date: | 7 Aug 2001 |